Telesis Bio, Inc. (TBIO)
Total Valuation
Telesis Bio has a market cap or net worth of $1.11 billion. The enterprise value is $1.12 billion.
| Market Cap | 1.11B |
| Enterprise Value | 1.12B |
Important Dates
The last earnings date was Thursday, May 11, 2023, after market close.
| Earnings Date | May 11, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 29.61 million shares outstanding. The number of shares has increased by 1.13% in one year.
| Shares Outstanding | 29.61M |
| Shares Change (YoY) | +1.13% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 37.39% |
| Owned by Institutions (%) | 43.15% |
| Float | 8.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.35 |
| Forward PS | 16.56 |
| PB Ratio | 30.21 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 39.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of 1.14.
| Current Ratio | 3.82 |
| Quick Ratio | 3.39 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -92.20% and return on invested capital (ROIC) is -77.50%.
| Return on Equity (ROE) | -92.20% |
| Return on Assets (ROA) | -52.10% |
| Return on Capital (ROIC) | -77.50% |
| Revenue Per Employee | $126,076 |
| Profits Per Employee | -$208,054 |
| Employee Count | 223 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 4.88 |
Taxes
In the past 12 months, Telesis Bio has paid $21,000 in taxes.
| Income Tax | 21,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.31% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -55.31% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 1.94 |
| Average Volume (30 Days) | 2,912,959 |
Short Selling Information
The latest short interest is 225,986, so 0.76% of the outstanding shares have been sold short.
| Short Interest | 225,986 |
| Short Previous Month | 182,749 |
| Short % of Shares Out | 0.76% |
| Short % of Float | 2.55% |
| Short Ratio (days to cover) | 3.04 |
Income Statement
In the last 12 months, Telesis Bio had revenue of $28.12 million and -$46.40 million in losses. Loss per share was -$1.57.
| Revenue | 28.12M |
| Gross Profit | 16.33M |
| Operating Income | -44.66M |
| Pretax Income | -46.38M |
| Net Income | -46.40M |
| EBITDA | -41.82M |
| EBIT | -45.25M |
| Loss Per Share | -$1.57 |
Balance Sheet
The company has $32.24 million in cash and $41.72 million in debt, giving a net cash position of -$9.47 million or -$0.32 per share.
| Cash & Cash Equivalents | 32.24M |
| Total Debt | 41.72M |
| Net Cash | -9.47M |
| Net Cash Per Share | -$0.32 |
| Equity / Book Value | 36.62M |
| Book Value Per Share | 1.24 |
| Working Capital | 31.70M |
Cash Flow
In the last 12 months, operating cash flow was -$44.26 million and capital expenditures -$4.48 million, giving a free cash flow of -$48.74 million.
| Operating Cash Flow | -44.26M |
| Capital Expenditures | -4.48M |
| Free Cash Flow | -48.74M |
| FCF Per Share | -$1.64 |
Margins
Gross margin is 58.08%, with operating and profit margins of -158.83% and -165.02%.
| Gross Margin | 58.08% |
| Operating Margin | -158.83% |
| Pretax Margin | -164.95% |
| Profit Margin | -165.02% |
| EBITDA Margin | -148.76% |
| EBIT Margin | -160.93% |
| FCF Margin | -173.36% |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -4.19% |
| FCF Yield | -4.41% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.13% |
| Shareholder Yield | -1.13% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |